Evidence map›Paper›PMID 32811132›Full record

ArticleThe Korean journal of internal medicine2021

Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia.

Heejoo Han, Ja Min Byun, Dong-Yeop Shin, Sung-Soo Yoon, Youngil Koh, Junshik Hong, Inho Kim, Chansup Lee, Hyeonjoo Yoo, Hongseok Yun and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Cancers · 2023
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Heejoo HanCenter for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Ja Min ByunDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Dong-Yeop ShinCenter for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Sung-Soo YoonCenter for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Youngil KohCenter for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Junshik HongCenter for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Inho KimDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Chansup LeeCancer Research Institute, Seoul National University Hospital, Seoul, Korea.
Hyeonjoo YooDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Hongseok YunCenter for Precision Medicine, Seoul National University Hospital, Seoul, Korea.
Man Jin KimDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Sung Im ChoDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Moon-Woo SeongDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Sung Sup ParkDepartment of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea.
Seoul National University Hospital · KRUniversity Hospital Heidelberg · DE

Funding

National Research Foundation of Korea 2016R1A5A1011974
6 · The paper itself

Abstract

BACKGROUND/

aimsUnderstanding leukemic stem cell (LSC) is important for acute myeloid leukemia (AML) treatment. However, association of LSC with patient prognosis and genetic information in AML patients is unclear.

methodsHere we investigated the associations between genetic information and the various LSC phenotypes, namely multipotent progenitor (MPP)-like, lymphoid primed multipotent progenitor (LMPP)-like and granulocyte-macrophage progenitors (GMP)-like LSC in 52 AML patients.

resultsIn secondary AML patients, MPP-like LSC was significantly higher than de novo AML (p = 0.0037). The proportion of MPP-like LSC was especially high in post-myeloproliferative neoplasm AML (p = 0.0485). There was no correlation between age and LSC phenotype. Mutations of KRAS and NRAS were observed in MPP-like LSC dominant patients, TP53 and ASXL1 mutations in LMPP-like LSC dominant patients, and CEBPA, DNMT3A and IDH1 mutations in GMP-like LSC dominant patients. Furthermore, KRAS mutation was significantly associated with MPP-like LSC expression (p = 0.0540), and TP53 mutation with LMPP-like LSC expression (p = 0.0276). When the patients were separated according to the combined risk including next generation sequencing data, the poorer the prognosis, the higher the LMPP-like LSC expression (p = 0.0052). This suggests that the dominant phenotype of LSC is one of the important factors in predicting the prognosis and treatment of AML.

conclusionLSC phenotype in AML is closely associated with the recurrent mutations which has prognostic implication. Further research to confirm the meaning of LSC phenotype in the context of genetic aberration is warranted.

Indexed as

Leukemia, Myeloid, AcuteHumansMutationPhenotypePrognosisStem CellsAcute myeloid leukemiaLeukemic stem cellNext generation sequencingPrognosis

Identifiers

PMID32811132
PMCPMC7969060
OpenAlexW3065441035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.